Clinical Trial Update: Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluating low-dose azacitidine with a short-term CAG regimen as a bridging treatment before allogeneic hematopoietic stem cell transplantatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome with Excess Blasts

Drugs mentioned

• Azacitidine (AZA) (azacitidine)
• CAG regimen

Snippet

Sponsor: Fujian Medical University | Conditions: MDS-EB | Phase 2, Phase 3 | Status: UNKNOWN